Triangle Pharmaceuticals has filed a marketing authorization application for its AIDS drug Coviracil to be sold in Europe.

After the markets closed Monday, Triangle (Nasdaq: VIRS) said the application had been made with the European Agency for the Evaluation of Medicinal Products and that it had been accepted for review. If approved, Triangle could sell the drug in the European Union.

What name will be used for the drug in Europe is under review, Triangle said. It will be called Coviracil in the United States.